Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
This case highlights fulminant cerebellitis as a life-threatening presentation of anti-GABA A R encephalitis and underscores the... She later stabilized with radiographic improvement and meaningful neurologic recovery.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These findings identify compartment-specific PPARδ activity as a targetable driver of immune cell fitness that can be harnessed to improve outcomes in immunotherapy-resistant tumors. Therapeutically, PPARδ-activated CD8 + T cells sensitize immunotherapy-resistant microsatellite stable metastatic colorectal cancer to checkpoint blockade in mice, and pharmacological or genetic PPARδ activation enhances human chimeric antigen receptor T cell function.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Specific dietary interventions, unexpectedly including some 'unhealthy' diets, may enhance cancer immunotherapy efficacy (real-world effectiveness in the trial) through gut microbiome modulation. This challenges traditional assumptions about diet's role in cancer treatment, suggesting that certain dietary patterns could potentially be leveraged to optimize immunotherapy outcomes.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Izalontamab brengitecan significantly improved PFS and OS vs chemotherapy in patients with recurrent or metastatic ESCC whose disease had progressed after first-line treatment. These findings support izalontamab brengitecan as a new second-line treatment for this population in China.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Teplizumab-specific recommendations are identified, with broader principles framed for adaptation across health systems. This article addresses who should lead care, how to approach eligibility and timing, how to assess β-cell reserve and infection risk, how to sequence treatment with diabetic ketoacidosis recovery and early education, and how to monitor treatment safely.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In this issue of Immunity, Luri-Rey et al. and Duong et al. show that two next-generation checkpoint strategies act through mature cDC1s, which assemble the costimulatory signals that set CD8⁺ T cell fate and determine therapeutic efficacy (real-world effectiveness in the trial). Published in Immunity, these peer-reviewed immunology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling. Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Thus, cDC1-T cell interactions are central to PD-L1×4-1BB activity, with antigen cross-presentation, dendritic-cell licensing, and IL-12 and 4-1BB costimulation converging to promote antitumor immunity. Treated tumors exhibited increased infiltration and spatial proximity of cDC1s and activated CD8 + T cells.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
In this issue of Immunity, Akama-Garren et al. demonstrate that PD-L1 expression on stromal cells enhances T-B cell collaborations and humoral immunity. Published in Immunity, these peer-reviewed immunology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
These findings reveal a non-canonical immunogenic role for PD-L1 in the GC and suggest that augmenting B cell responses could improve the efficacy (real-world effectiveness in the trial) of PD-L1 blockade. Mechanistically, BRC-specific deletion of PD-L1 enhanced TFH cell production of Sostdc1 and TFR cell differentiation, destabilizing T-B contacts in the GC.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In this nonrandomized clinical trial, a single dose of mivocabtagene autoleucel resulted in immunotherapy-free remissions with a consistent, well-tolerated safety profile, demonstrating a highly effective therapy in antibody-positive SPS with the potential for durable remissions. Long-term follow-up is ongoing.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Our findings outline the spatial organization, signaling programs and interactions of cDC1-like cells that initiate intratumoral lymphoid structures and establish cellular reprogramming as a strategy toward overcoming resistance to immunotherapy. ImgTLSs sustained B and T cell responses and promoted systemic immunity through expansion of shared clonotypes in distant, untreated tumors.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Serious TEAEs were reported for 10 patients, including eight patients with grade 3 or higher events (non-hematologic, 13.5% (5/37); hematologic, 13.5% (5/37)). RP2D was selected based on overall safety and tolerability as well as preliminary anti-tumor activity in Agni-01 Phase 1.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Preoperative BOT + BAL elicits pathological responses in patients with pMMR or dMMR CC, supporting the combination as a promising strategy to expand ICI benefits to the early-stage setting. . Eight (29%) and 15 (54%) patients treated with BOT and BOT + BAL, respectively, experienced immune-related side effects, most commonly flu-like syndrome and diarrhea.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Our findings provide evidence-based disability thresholds, highlight novel prognostic biomarkers, and pragmatically guide LGI1-Ab-E care, pending randomized clinical trials. Hence, using mRS 0-1 as a favourable outcome, we identified worse mRS at nadir associated with greater one-year disability (OR = 2.56, 95%CI = 1.56-4.20, p = 0.0003), and each month of delayed immunotherapy associated with a 16% increased risk of disability (HR = 1.16, 95%CI = 1.06-1.35, p = 0.004).
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
As well, two bispecific ADCs, respectively targeting EGFR-c-MET and EGFR-B7-H3, appear active against multiple solid tumor types. The antibody-drug conjugate field is increasingly looking to go after more than one target at a time.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Together, these findings establish hnRNPA2B1 as an RNA-mediated epigenetic regulator sustaining functional exhausted T cell states in tumors. Mechanistically, hnRNPA2B1 forms nuclear puncta and stabilizes RNAs involved in chromatin organization, thereby maintaining chromatin accessibility that restrains exhaustion-associated programs while preserving proliferative and cytotoxic potential.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain. Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These findings support further evaluation of visugromab in MIBC. . There were no treatment-related discontinuations or treatment-related delays to surgery; grade 3-4 treatment-related side effects occurred in two (13%) and three (20%) patients treated with N + V or N + P, respectively.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
The safety profile remained consistent with prior reports. Among biomarker (measurable biological signal)-evaluable patients in the PD-L1 ≥1% subgroup, analyses revealed an association between worse outcomes with nivolumab and high peripheral or tumor LAG-3 + CD8 cell levels.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Initial Phase 2 results further corroborated the safety of invika and expanded its preliminary evidence of clinically meaningful anti-tumor activity in ICB-resistant solid tumors, supporting further evaluation in the ongoing Phase 2. . Invika selectively and potently expanded peripheral and intratumoral Vβ6/Vβ10 T cells, of a predominantly memory-like phenotype, dose-dependently, peaking at the OBDs.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Over the past 20 years, a decreasing proportion of DILI cases are attributed to antibiotics while an increasing proportion are attributed to HDS products and antineoplastics. Oncology patients and those > 65 years old have significantly higher overall and liver-related risk of death.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
This randomized clinical trial found that treatment with RT-DXd demonstrated promising activity, with mostly low-grade toxic effects in immune-positive, ERBB2-negative EBC. Unlike immune-negative patients, many immune-positive patients who experienced pCR avoided standard chemotherapy, including anthracyclines, supporting further evaluation in biomarker (measurable biological signal)-selected populations.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In this Phase 2 nonrandomized clinical trial, the immunotherapy regimen evaluated was associated with sustained long-term survival, but no clear evidence of improved survival over outcomes reported in other studies evaluating surgery alone in this patient population was observed. The high pCR rates and durable responses observed may provide useful information for designing future clinical studies, including randomized trials investigating organ-preserving strategies.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Overall, the interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy (real-world effectiveness in the trial) following vaccination. . biomarker (measurable biological signal) analysis was suggestive of biologic activity of the vaccine in six of ten patients and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Investigators across disciplines discuss how they are reimagining strategies to drive the immune system in contexts of cancer, autoimmunity, and beyond. The introduction of immune checkpoint blockade revolutionized cancer treatments.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
1 min read·Immunity·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”